Objective To observe and compare the efficacy of erlotinib and gefinitib in the treatment of non-small cell lung cancer (NSCLC) with brain metastasis. Method 100 cases of NSCLC patients with brain metastasis were enrolled and randomized into gefitinib group (n=50) or erlotinib group (n=50) using random number table, with gefinitib given in the former and erlotinib administered in the latter, the clinical effect and adverse reactions of both groups were compared. Result The disease control rate (DCR) was 96.0% vs 92.0%, and response rate (RR) was 76.0% vs 76.0% in gefitinib group and erlotinib group, respectively, with no significant difference observed (P>0.05);As for adverse reactions, higher incidences of rash, nausea and vomiting were observed in erlotinib group compared with gefitinib group (P<0.05), while the incidences of diarrhea and liver dysfunction were similar in both groups (P>0.05), and the overall adverse reactions were less in gefitinib group compared with erlotinib group (P>0.05). Conclusion Erlotinib and gefinitib are comparable effective in the treatment of non-small cell lung cancer patients with brain metastasis, while less adverse reactions are in-duced by gefinitib compared with erlotinib treatment, making it more clinically practicable.%目的：观察并比较厄洛替尼和吉非替尼靶向治疗非小细胞肺癌脑转移的疗效和不良反应发生情况。方法将100例非小细胞肺癌脑转移患者按随机数字表法分为两组各50例，分别给予吉非替尼和厄洛替尼治疗，比较两组不良反应及治疗效果。结果吉非替尼组和厄洛替尼组的疾病控制率分别为96.0%、92.0%，总有效率分别为76.0%、76.0%，两组比较，差异无统计学意义（P﹥0.05）；在不良反应方面，两组患者治疗后均出现不良反应，厄洛替尼组皮疹、恶心呕吐不良反应的发生率高于吉非替尼组（P﹤0.05），但在腹泻和肝功能损害发生率方面，两组比较差异无统计学意义（P﹥0.05），吉非替尼组总不良反应发生率低于厄洛替尼组（P﹤0.05）。结论非小细胞肺癌脑转移患者应用厄洛替尼和吉非替尼靶向治疗效果相当，但吉非替尼导致的总不良反应发生率低于厄洛替尼，值得在非小细胞肺癌脑转移患者治疗中临床推广。
展开▼
